-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest announcement from the Center for Drug Evaluation (CDE) of the State Drug Administration of China, Zai Lab has submitted three clinical trial applications for efgartigimod injection, which were accepted by the CDE
In January 2021, Zai Lab and argenx reached an exclusive license cooperation, obtained the exclusive development and commercialization rights of efgartigimod in Greater China, and will be responsible for the global registration clinical research and development of multiple indications of the candidate drug in China
According to a press release issued by argenx in May 2020, data from the ADAPT study showed that 67.
The acceptance of the clinical trial application of Efgartigimod injection by CDE means that the drug is expected to start clinical trials in China soon